A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Salivary Gland Cancer
    Head And Neck Cancers
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Must have histologically or cytologically confirmed salivary gland cancer that is recurrent/metastatic or unresectable/locally advanced, with AR expression
    2. Must have not had prior AR-targeted therapy
    3. Have treated brain metastases

You may not be eligible for this study if the following are true:

    1. Patients who have not recovered from adverse events due to prior anti-cancer therapy
    2. Patients who are receiving any other investigational agents
    3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to darolutamide or leuprolide acetate



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.